WO2024194884 - PREPARATION AND PHARMACEUTICAL APPLICATION OF A NOVEL PENTACYCLIC TRITERPENOID
National phase entry is expected:
Publication Number
WO/2024/194884
Publication Date
26.09.2024
International Application No.
PCT/IN2024/050255
International Filing Date
12.03.2024
Title **
[English]
PREPARATION AND PHARMACEUTICAL APPLICATION OF A NOVEL PENTACYCLIC TRITERPENOID
[French]
PRÉPARATION ET APPLICATION PHARMACEUTIQUE D'UN NOUVEAU TRITERPÉNOÏDE PENTACYCLIQUE
Applicants **
SUTHAR, Sharad Kumar
Inventors
MONGA, Jitender
Priority Data
202321019822
22.03.2023
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1958 | |
| EPO | Filing, Examination, Granting | 8900 | |
| Japan | Filing, Examination, Granting | 1864 | |
| South Korea | Filing, Examination, Granting | 1392 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
18,854
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
LA; 2-methylene-3-oxo-226-angeloyloxy-olean-12-en-28-oic acid) was developed from Lantadene A (LA). The newly developed compound displayed potent cytotoxicity against cancer cell lines, with highly cytotoxic to kidney and prostate cancer cell lines. The biological data of the compound indicates the potential pharmaceutical use of the compound in cancer, inflammation, and oxidative stress-associated inflammation and injuries, for example, autoimmune diseases, renal inflammation and injury, and eye inflammation and injury.[French]
Un nouveau triterpénoïde pentacyclique de la série oléanane appelé composé de formule I (2CH2LA ; acide 2-méthylène-3-oxo-22β-angéloyloxy-oléan-12-én-28-oïque) a été développé à partir du lantadène A (LA). Le composé nouvellement développé présente une cytotoxicité puissante contre des lignées cellulaires cancéreuses, avec une haute cytotoxicité vis-à-vis de lignées cellulaires de cancer de la prostate et des reins. Les données biologiques du composé indiquent l'utilisation pharmaceutique potentielle du composé dans le cancer, l'inflammation ainsi que l'inflammation et les lésions associées au stress oxydatif, par exemple, des maladies auto-immunes, l'inflammation et les lésions rénales, ainsi que l'inflammation et les lésions oculaires.